[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658680":3},{"organization":4,"outcomesModule":7,"designInfo":35,"detailedDescription":34,"studyPopulation":34,"armGroups":41,"interventions":48,"overallOfficials":34,"centralContacts":54,"locations":60,"responsibleParty":78,"collaborators":34,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":34,"eligibilityCriteria":85,"healthyVolunteers":82,"sex":86,"minAge":87,"maxAge":34,"enrollmentInfo":88,"targetDuration":34,"studyType":91,"phases":92,"briefSummary":93,"conditions":94,"keywords":34,"overallStatus":96,"whyStopped":34,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Zhongshan Ophthalmic Center, Sun Yat-sen University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":34},[9],{"measure":10,"description":11,"timeFrame":12},"Corneal thickness","Corneal thickness was measured preoperatively and postoperatively using an iVue OCT (OPTOVUE) or another OCT instrument, and the changes were compared.","Preoperatively and at postoperative day 1; at 1 and 2 weeks; and at 1, 2, 3, 6, and 12 months.",[14,17,20,23,27,30],{"measure":15,"description":16,"timeFrame":12},"Best-corrected visual acuity (BCVA)","Preoperative and postoperative visual acuity was assessed using the ETDRS chart.",{"measure":18,"description":19,"timeFrame":12},"Spherical equivalent (SE)","Preoperative and postoperative SE was measured using a phoropter and an autorefractor, and differences before and after surgery as well as between the two groups were compared.",{"measure":21,"description":22,"timeFrame":12},"Corneal edema and opacity","The degree of corneal edema and opacity was examined by slit-lamp microscopy.",{"measure":24,"description":25,"timeFrame":26},"Corneal endothelial cell count","Postoperative corneal endothelial cell density was measured using laser confocal microscopy (Heidelberg Engineering, Germany) or a corneal endothelial specular microscope, and changes were compared.","At postoperative day 1 and at 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, and 12 months.",{"measure":28,"description":29,"timeFrame":26},"Donor graft detachment","Graft adhesion\u002Fapposition was evaluated by slit-lamp microscopy and OCT.",{"measure":31,"description":32,"timeFrame":33},"Intraocular pressure (IOP)","Preoperative and postoperative IOP was measured using a non-contact tonometer.","Preoperatively and at 1, 3, 6, and 12 months postoperatively.",null,{"allocation":36,"interventionModel":37,"interventionModelDescription":34,"primaryPurpose":38,"observationalModel":34,"timePerspective":34,"maskingInfo":39},"NA","SINGLE_GROUP","TREATMENT",{"masking":40,"maskingDescription":34,"whoMasked":34},"NONE",[42],{"label":43,"type":44,"description":45,"interventionNames":46},"Postoperative corneal thickness","EXPERIMENTAL","To observe postoperative corneal thickness in patients with bullous keratopathy treated by endothelial keratoplasty using residual donor tissue following previous corneal transplantation.",[47],"Procedure: Endothelial keratoplasty using residual donor tissue",[49],{"type":50,"name":51,"description":52,"armGroupLabels":53,"otherNames":34},"PROCEDURE","Endothelial keratoplasty using residual donor tissue","Endothelial keratoplasty using residual donor tissue from previous corneal transplantation",[43],[55],{"name":56,"role":57,"phone":58,"phoneExt":34,"email":59},"Xiaojuan Dong","CONTACT","8613552338060","qingerdong@126.com",[61],{"facility":62,"status":34,"city":63,"state":64,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University","Guangzhou","Guangdong","510070","China","CN",{"type":69,"coordinates":70},"Point",[71,72],113.25,23.11667,{"lat":72,"lon":71},[75],{"name":76,"role":57,"phone":77,"phoneExt":34,"email":59},"Ting Huang","8613682205425",{"type":79,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100658680","utilization-of-residual-donor-tissue-for-regrafting-in-bullous-keratopathy-after-corneal-transplantation-100658680",false,"NCT07855601","Utilization of Residual Donor Tissue for Regrafting in Bullous Keratopathy After Corneal Transplantation","Inclusion Criteria:\n\n* Patients with bullous keratopathy of various etiologies, with a corneal thickness of ≥650 μm, refractory to medical treatment.\n* Aged ≥18 years.\n* The subject or their legally authorized guardian voluntarily consents to participate in this study and signs the informed consent form, with good compliance and willingness to attend follow-up visits.\n\nExclusion Criteria:\n\n* Loss of vision in the fellow eye.\n* Corneal or ocular surface infection within 30 days prior to enrollment.\n* Severe dry eye, with Schirmer's test \\\u003C 5 mm.\n* Concurrent diseases that may affect the transplantation or prognosis, such as advanced glaucoma or retinal diseases.\n* Ocular surface malignancy.\n* Severe cicatrizing ocular disease; conjunctival scarring with fornix shortening.\n* Recent HbA1c \\> 6.5%, or uncontrolled diabetes mellitus.\n* Severe impairment of vital organs, including the heart, liver, or kidneys.\n* Severe hematologic or endocrine disorders, or a history of such disorders.\n* Active autoimmune disease.\n* Current signs of infection, including fever or ongoing antibiotic therapy.\n* Psychiatric disorders.\n* Pregnant or lactating women, or women planning pregnancy within 2 years.\n* Participation in other clinical studies or trials within 3 months.\n* Subjects who lack compliance with the study or the capacity to sign the informed consent form.","ALL","18 Years",{"count":89,"type":90},20,"ESTIMATED","INTERVENTIONAL",[36],"Postoperative endothelial cell loss following Descemet stripping endothelial keratoplasty (DSEK) remains a well-recognized clinical concern, with long-term follow-up demonstrating approximately 50% reduction in endothelial cell density by 5 years. Compounding this challenge, the critical shortage of corneal donors has severely limited the expansion of corneal transplantation programs in developing countries. In conventional penetrating keratoplasty, only the central 7-mm optical zone is typically harvested, whereas the peripheral donor tissue-whose endothelial cells are believed to exhibit superior viability-is routinely discarded.\n\nTo address these limitations, we describe the first-in-human use of three residual peripheral donor tissue segments, obtained after conventional keratoplasty, which were combined to perform corneal endothelial transplantation. This innovative approach substantially enhanced donor tissue utilization. Postoperatively, the patient achieved sustained corneal transparency with visual acuity improving from 20\u002F500 to 20\u002F50. Notably, the intersegmental gaps resolved progressively over time.\n\nExtending this proof-of-concept case, we subsequently investigated the long-term stability and safety of residual donor tissue endothelial keratoplasty for bullous keratopathy, with comprehensive evaluation of postoperative visual acuity, intraocular pressure, corneal endothelial cell density, and refractive outcomes. This study aims to establish evidence-based support for the safety and efficacy of utilizing residual graft tissue in corneal endothelial transplantation.",[95],"Bullous Keratopathy","NOT_YET_RECRUITING","2026-09-28",{"date":99,"type":100},"2026-10-02","ACTUAL",{"date":102,"type":90},"2026-10-17",{"date":104,"type":90},"2028-10-18",{"name":5,"class":6},1]